Revolutionizing Diabetes Treatment: Tirzepatide's Approval and Synergy with Oxford Therapeutics'

CANARY WHARF, U.K. - Sept. 9, 2023 - PRLog -- The National Institute for Health and Care Excellence (NICE) has granted its seal of approval to Tirzepatide. This heralds an exciting opportunity for collaboration with Oxford Therapeutics Ltd and their innovative "My Weigh Less" psychology-focused downloadable weight-loss treatment.

Oxford Therapeutics, a stakeholder in NICE, offers a downloadable psychology-focused weight-loss program designed for patient convenience, accessible on smartphones, tablets, or desktop computers. This program draws from the success of their acclaimed GMB program and is fortified with over 15,000 hours of one-on-one clinical expertise.

While Tirzepatide has emerged as a potent weight-loss ally to patients grappling with obesity-related complications such as high blood pressure. This medication is recommended for individuals with a body mass index (BMI) exceeding 35 or those unable to use insulin injections.

Eli Lilly, the pharmaceutical pioneer behind Tirzepatide, extends its ambitions beyond diabetes treatment, actively seeking approval for its utilization in weight-loss treatments within the NHS. A decision from the Medicines and Healthcare products Regulatory Agency (MHRA) is eagerly anticipated in the months ahead. Encouragingly, clinical trials hint at Tirzepatide's potential to achieve weight loss of up to 26 per cent—an impressive stride beyond the approximately 15 per cent achieved by Novo Nordisk's Wegovy.

Though Tirzepatide's arrival in the UK is anticipated for early 2024, the product's demand is already palpable, echoing the successes of Ozempic and Wegovy. Eli Lilly is diligently exploring alternative formulations of the drug, including a vial and a user-friendly multidose KwikPen, to bolster its supply.

In the UK, approximately 4.5 million people grapple with Type 2 diabetes, and many confront shortages of GLP1 medications, including Semaglutide, prompting them to explore alternatives like insulin. Douglas Twenefour, head of care at Diabetes UK, underscores that ongoing medication shortages are sowing stress and uncertainty among countless Type 2 diabetes patients. Thus, Tirzepatide's approval offers a beacon of hope. Twenefour also calls for additional measures to ensure a consistent supply of these critical medications.

David Webb, Chief Pharmaceutical Officer at NHS England, lauds this announcement as "great news," especially in light of disruptions in the supply of key diabetes drugs. He adds that Tirzepatide will fill a crucial gap in available treatments and can be prescribed alongside diet and exercise, signifying its potential to revolutionize diabetes care in the UK.

As the healthcare landscape evolves with this ground breaking diabetes treatment, Oxford Therapeutics' "My Weigh Less" psychology-focused, downloadable weight-loss program emerges as the ideal complement. While weight-loss injections are effective during use, the risk of weight "creep" and regain remains a concern. Therefore, it is believed that a psychology-focused intervention, like "My Weigh Less," presents the optimal model to ensure sustained success in weight management alongside Tirzepatide's diabetes management. Together, they offer a beacon of hope for millions in the UK, promising improved health outcomes and a brighter future.
https://myweighless.com